ProQR Therapeutics (PRQR) Enterprise Value (2013 - 2025)
ProQR Therapeutics recorded quarterly Enterprise Value of -$107.6 million in Q4 2025, up 32.62% quarter-over-quarter from -$159.7 million in Q4 2024, and up 32.62% year-over-year from -$81.1 million in Q4 2024.
ProQR Therapeutics' Enterprise Value history runs 13 years deep, the most recent figure standing at -$107.6 million for Q4 2025.
- In Q4 2025, Enterprise Value rose 32.62% year-over-year to -$107.6 million; the TTM figure through Dec 2025 stood at -$107.6 million (up 32.62% YoY), while the FY2025 annual figure was -$107.6 million, up 32.62% from the prior year.
- Enterprise Value came in at -$107.6 million for Q4 2025 at ProQR Therapeutics, up from -$159.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$91.5 million in Q1 2021 to a low of -$219.1 million in Q4 2021.
- A 5-year average of -$146.6 million and a median of -$145.1 million in 2023 frame the typical range for Enterprise Value.
- On a YoY basis, Enterprise Value climbed as much as 99.93% in 2021 and fell as far as 139.65% in 2021.
- ProQR Therapeutics' Enterprise Value stood at -$219.1 million in 2021, then surged by 55.28% to -$98.0 million in 2022, then sank by 30.59% to -$128.0 million in 2023, then dropped by 24.77% to -$159.7 million in 2024, then soared by 32.62% to -$107.6 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$107.6 million, -$159.7 million, and -$128.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | -107.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -107.57 Mn |
| Dec 31, 2024 | -159.66 Mn |
| Dec 31, 2023 | -127.96 Mn |
| Sep 30, 2023 | -131.51 Mn |
| Jun 30, 2023 | -140.40 Mn |
| Mar 31, 2023 | -149.82 Mn |
| Dec 31, 2022 | -97.98 Mn |
| Sep 30, 2022 | -189.22 Mn |
| Jun 30, 2022 | -167.13 Mn |
| Mar 31, 2022 | -210.78 Mn |
| Dec 31, 2021 | -219.09 Mn |
| Sep 30, 2021 | -167.11 Mn |
| Jun 30, 2021 | -93.28 Mn |
| Mar 31, 2021 | -91.48 Mn |
| Dec 31, 2020 | -91.42 Mn |
| Sep 30, 2020 | -132.04 Mn |
| Jun 30, 2020 | -123.31 Mn |
| Mar 31, 2020 | -123.59 Bn |
| Dec 31, 2019 | -123.92 Mn |
| Sep 30, 2019 | -117.48 Mn |
| Jun 30, 2019 | -118.63 Mn |
| Mar 31, 2019 | -120.01 Mn |
| Dec 31, 2018 | -120.51 Mn |
| Sep 30, 2018 | -55.95 Mn |
| Jun 30, 2018 | -57.40 Mn |
| Mar 31, 2018 | -59,091.20 Bn |
| Dec 31, 2017 | -56.63 Mn |
| Sep 30, 2017 | -69,563.75 Bn |
| Jun 30, 2017 | -65.09 |
| Mar 31, 2017 | -63,072.09 |
| Dec 31, 2016 | -63.92 Mn |
| Sep 30, 2016 | -72,463.81 |
| Dec 31, 2015 | -103.98 Mn |
| Sep 30, 2015 | -125.39 Bn |
| Mar 31, 2015 | -128.59 Mn |
| Dec 31, 2014 | -140.90 Mn |
| Sep 30, 2014 | -50.69 Mn |
| Mar 31, 2014 | -5.66 Mn |
| Dec 31, 2013 | -5.62 Mn |
| Sep 30, 2013 | -3.52 Mn |